Globenewswire·2026-02-06 12:55Core Viewpoint - Polyrizon Ltd. has entered into a development agreement with Clearmind Medicine Inc. to leverage Polyrizon's intranasal delivery platform for the clinical development of Clearmind's drug candidate MEAI, aimed at treating addiction-related and other CNS conditions [1][2][3] Group 1: Collaboration Details - The collaboration aims to advance an intranasal formulation of MEAI to support Clearmind's future clinical development programs [2] - Polyrizon's proprietary intranasal technology is designed to enable targeted and efficient delivery of drugs, potentially offering significant value in Clearmind's clinical pathway [3] Group 2: Polyrizon's Technology - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The company's Capture and Contain TM hydrogel technology is designed to enhance bioadhesion and prolong retention at the nasal site for drug delivery [4][6] Group 3: Clearmind's Focus - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address underserved health issues, including alcohol use disorder [7] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [8]